

Special Issue

SARS-CoV-2, Influenza and Other Respiratory Viruses: Epidemiology, Burden of Disease, and Preventive Measures

Message from the Guest Editors

Respiratory viruses are among the most frequent causative agents of disease in humans, with substantial impact on morbidity and mortality worldwide. However, little is known about the real burden of disease of many infections caused by respiratory viruses. Moreover, since the onset of the COVID-19 pandemic, most countries have reported historically low circulation, and whether viruses such as influenza and RSV will have a usual circulation in the future is still uncertain. Finally, the current pandemic has greatly accelerated advances in preventive measure research, especially vaccines, vaccine production, and vaccination strategies. This Special Issue of *Vaccines* on “SARS-CoV-2, Influenza, and Other Respiratory Viruses: Epidemiology, Burden of Disease, and Preventive Measures” aims to achieve a more extensive understanding of recent scientific knowledge and current trends around the epidemiology, the burden of disease, and the preventive measures of SARS-CoV-2, influenza, and other respiratory viruses. Research and review papers, as well as viewpoints, are welcome.

Guest Editors

Dr. Marco Del Riccio

Dr. William John Paget

Dr. Saverio Caini

Deadline for manuscript submissions

closed (30 September 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/146011

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).